AngioLab (XKRX:251280) Gross-Profit-to-Asset % : 2.26% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. AngioLab's annualized Gross Profit for the quarter that ended in Dec. 2023 was ₩100.9 Mil. AngioLab's average Total Assets over the quarter that ended in Dec. 2023 was ₩4,457.8 Mil. Therefore, AngioLab's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 2.26%.

AngioLab Gross-Profit-to-Asset % Historical Data

The historical data trend for AngioLab's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Gross-Profit-to-Asset % Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

6.21

-19.78

14.71

13.84

2.26

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			6.21	-19.78	14.71	13.84	2.26

Competitive Comparison of AngioLab's Gross-Profit-to-Asset %

For the Biotechnology subindustry, AngioLab's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AngioLab's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AngioLab's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where AngioLab's Gross-Profit-to-Asset % falls into.

AngioLab Gross-Profit-to-Asset % Calculation

AngioLab's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	100.926	/	( (4997.03	+	3918.531)	/ 2 )
	=	100.926	/	4457.7805
	=	2.26 %

AngioLab's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	100.926	/	( (4997.03	+	3918.531)	/ 2 )
	=	100.926	/	4457.7805
	=	2.26 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is one times the annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

AngioLab Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of AngioLab's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines